Active, not recruitingPhase 2NCT04729959
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Stephen J BagleyNRG Oncology
- Intervention
- Atezolizumab(biological)
- Enrollment
- 59 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Kaiser Permanente-Ontario, Ontario, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Kaiser Permanente-San Diego Zion, San Diego, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04729959 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco